Quick Answer
TG THERAPEUTICS, INC. reported Revenue (ASC 606) of $616.29 million for fiscal year 2025.
TG THERAPEUTICS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $616.29M | +87.3% |
| 2024 | $329.00M | +40.8% |
| 2023 | $233.66M | +8290.0% |
| 2022 | $2.79M | -58.4% |
| 2021 | $6.69M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $161.71M | +92.8% | +14.6% |
| June 30, 2025 | $141.15M | +92.1% | +16.8% |
| March 31, 2025 | $120.86M | +90.4% | +44.1% |
| September 30, 2024 | $83.88M | -49.4% | +14.2% |
| June 30, 2024 | $73.47M | +357.0% | +15.7% |
| March 31, 2024 | $63.47M | +713.5% | -61.7% |
| September 30, 2023 | $165.81M | +176298.9% | +931.6% |
| June 30, 2023 | $16.07M | +2606.1% | +106.0% |
- TG THERAPEUTICS, INC. showed an increase of +87.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2021–2025 period, TG THERAPEUTICS, INC.’s revenue (asc 606) has grown by 9113.4% (from $6.69 million to $616.29 million).
- The most recent figure is from TG THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: